Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters

Previous studies have suggested that breast cancer in young women has more aggressive biological features and poorer prognosis. However, the role of biological markers in these patients is not well understood. We aimed to learn more about this disease in a cohort of 125 young women from Singapore, Japan and Hong Kong, aged 35 years or less, with invasive breast cancer by evaluating the expression of vimentin and the basal cytokeratins CK14, CK5/6 and 34βE12. Both standard paraffin sections and tissue microarrays were used in the immunohistochemical evaluation of expression patterns of these four biological markers. CK5/6, CK14, vimentin and 34βE12, in increasing order of proportion, were detected in invasive carcinomas. Basal cytokeratins and vimentin showed significant inverse relationship with estrogen and progesterone receptor status while CK14 expression was found to be directly associated with c-erbB2 status. Basal cytokeratins and vimentin immunoreactivities were directly associated with CD117 and EGFR expression. Vimentin and 34βE12 immunopositivity correlated with tumor size, while vimentin was associated with higher histological grade. Our findings are in concert with reports that expression of basal cytokeratins and vimentin is correlated with adverse pathological parameters.

[1]  P. V. van Diest,et al.  The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.

[2]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Lubinski,et al.  Intermediate filament typing of tumor cells in fine needle aspirates by means of monoclonal antibodies. , 1986, Acta cytologica.

[4]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[5]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Wiseman,et al.  Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival , 2005, Cancer.

[7]  P. Maxwell,et al.  Vimentin expression in benign and malignant breast epithelium. , 1993, Journal of clinical pathology.

[8]  S. Schnitt,et al.  The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  L. Puett,et al.  Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. , 1988, Journal of the National Cancer Institute.

[10]  R. Moll,et al.  Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas , 1998, Virchows Archiv.

[11]  D L Rimm,et al.  Amplification of tissue by construction of tissue microarrays. , 2001, Experimental and molecular pathology.

[12]  G. Striker,et al.  Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. , 1990, The American journal of pathology.

[13]  D. Rimm,et al.  Immunohistochemical Biomarkers in Patients with Early‐Onset Breast Carcinoma by Tissue Microarray , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Tan,et al.  Cytokeratins in Papillary Lesions of the Breast: Is There a Role in Distinguishing Intraductal Papilloma From Papillary Ductal Carcinoma In Situ? , 2005, The American journal of surgical pathology.

[15]  P. Tan,et al.  Breast carcinoma in women 35 years and younger: a pathological study , 2006, Pathology.

[16]  S. Lakhani,et al.  CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation , 2001, British Journal of Cancer.

[17]  W. Han,et al.  Young age: an independent risk factor for disease-free survival in women with operable breast cancer , 2004, BMC Cancer.

[18]  B. Teh,et al.  Parafibromin expression in breast cancer: a novel marker for prognostication? , 2007, Journal of Clinical Pathology.

[19]  D. Horsfall,et al.  Vimentin expression is not associated with poor prognosis in breast cancer , 1996, International journal of cancer.

[20]  Carlos Caldas,et al.  Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[21]  K. Shroyer,et al.  C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. , 2006, Human pathology.

[22]  P. Tan,et al.  Over‐expression of c‐erbB‐2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women , 2006, Pathology.

[23]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[25]  Puay Hoon Tan,et al.  Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations , 2004, Clinical Cancer Research.

[26]  S. Schnitt,et al.  Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.

[27]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[28]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[29]  A. Leong,et al.  Co‐expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium , 1989, The Journal of pathology.

[30]  M. Hendrix,et al.  Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. , 1997, The American journal of pathology.

[31]  S. Pileri,et al.  DIFFERENTIATION PATHWAYS IN PRIMARY INVASIVE BREAST CARCINOMA AS SUGGESTED BY INTERMEDIATE FILAMENT AND BIOPATHOLOGICAL MARKER EXPRESSION , 1996, The Journal of pathology.

[32]  V. Valero,et al.  HER‐2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger , 2005, Cancer.

[33]  J. Inazawa,et al.  Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid‐tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation , 2005, Cancer Science.

[34]  E. Fuchs.  Keratins as biochemical markers of epithelial differentiation. , 1988, Trends in genetics : TIG.

[35]  Wolfgang Henrich,et al.  The prognostic significance of epithelial-mesenchymal transition in breast cancer. , 2002, Anticancer research.

[36]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.